Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks
Public ClinicalTrials.gov record NCT00147498. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Compare 3 Dose Levels Of CP-690,550 Versus Placebo, Administered Orally Twice Daily (BID) For 6 Weeks, In The Treatment Of The Signs And Symptoms Of Subjects With Active Rheumatoid Arthritis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study's objective is to compare the efficacy of 3 dose levels of oral CP-690,550 monotherapy (5 mg, 15 mg, and 30 mg twice daily \[BID\]) versus placebo administered over 6 weeks for the treatment of the signs and symptoms of subjects with active rheumatoid arthritis (RA).
Study identification
- NCT ID
- NCT00147498
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 264 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2004
- Primary completion
- May 31, 2006
- Completion
- May 31, 2006
- Last update posted
- Jan 29, 2013
2005 – 2006
United States locations
- U.S. sites
- 24
- U.S. states
- 12
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Upland | California | 91786 | — |
| Pfizer Investigational Site | Clearwater | Florida | 33765 | — |
| Pfizer Investigational Site | Miami | Florida | 33173 | — |
| Pfizer Investigational Site | New Port Richey | Florida | 34652 | — |
| Pfizer Investigational Site | Ocala | Florida | 34474-7455 | — |
| Pfizer Investigational Site | Orlando | Florida | 32804 | — |
| Pfizer Investigational Site | Port Richey | Florida | 34668 | — |
| Pfizer Investigational Site | Tampa | Florida | 33614 | — |
| Pfizer Investigational Site | Dubuque | Iowa | 52001-7313 | — |
| Pfizer Investigational Site | Dubuque | Iowa | 52002 | — |
| Pfizer Investigational Site | Concord | New Hampshire | 03301 | — |
| Pfizer Investigational Site | Plainview | New York | 11803 | — |
| Pfizer Investigational Site | Charlotte | North Carolina | 28210 | — |
| Pfizer Investigational Site | Hickory | North Carolina | 28601 | — |
| Pfizer Investigational Site | Hickory | North Carolina | 28602 | — |
| Pfizer Investigational Site | Dayton | Ohio | 45402 | — |
| Pfizer Investigational Site | Ducansville | Pennsylvania | 16635 | — |
| Pfizer Investigational Site | Johnstown | Pennsylvania | 15904 | — |
| Pfizer Investigational Site | Charleston | South Carolina | 29406 | — |
| Pfizer Investigational Site | Columbia | South Carolina | 29204 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37203 | — |
| Pfizer Investigational Site | Dallas | Texas | 75231-4496 | — |
| Pfizer Investigational Site | Everett | Washington | 98201 | — |
| Pfizer Investigational Site | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00147498, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 29, 2013 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00147498 live on ClinicalTrials.gov.